Daewoo Engineering & Construction Co. will develop wearable robots that can be worn by construction workers that could help prevent musculoskeletal disorders and maintain productivity.
The wearable robots consist of a waist support robot and a walking assistance robot. It will have sensors that will gather and analyze information about the workers' posture, weight, and working practices.
If their safety and efficacy are proven, Daewoo E&C will increase the supply of these robots to other industrial areas.
The company was selected in a contest held by the Korea Institute for Robot Industry Advancement to work in cooperation with local robotics startup Wirobotics and the Korea Orthopedics and Rehabilitation Center to develop and demonstrate smart work care services using wearable robot solutions.
The three parties, including Daewoo E&C, proposed the wearable robot and smart work care services concerning construction workers’ musculoskeletal issues and sustainable productivity.


Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Oil Prices Surge Past $100 as U.S.-Iran Peace Hopes Collapse
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 



